Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2021

View Archived Issues

Bayer initiates phase II study of runcaciguat in nonproliferative diabetic retinopathy

Boehringer Ingelheim starts enrolling participants in phase I study of BI-1323495

VB-85247, a member of a novel class of macrocyclic STING agonists

Brain metastases of breast cancer depend on fatty acid synthesis

FDA clears IND for phase II study of MIT-001 as therapy of CCRT-induced oral mucositis in HNSCC

Enrollment begins in phase III study of futibatinib in CCA harboring FGFR2 gene rearrangements

First patient dosed in phase II AFFINITY basket study of atrasentan

Biotest adds additional patient group to ongoing phase III AdFIrst study of BT-524

Alkermes collaborates with MSD to evaluate nemvaleukin alfa in combination with Keytruda

Shionogi and Hsiri Therapeutics patent compounds for mycobacterial infections

X-Chem discloses new HAOX1 inhibitors

Terns identifies thyroid hormone receptor beta agonists

Vincere Biosciences presents new USP30 inhibitors

First cohort fully enrolled in WWRD Study of AVM-0703

Cell Biotech divulges vector constructs for colon cancer

Trodelvy granted expanded approval by FDA for metastatic TNBC

Phenex Pharmaceuticals develops novel class of heme-displacing IDO-1 inhibitors

Subcutaneous injection of Tysabri approved in Europe for relapsing-remitting MS

Enrollment ongoing in phase II study of IC-14 chimeric antibody in patients with COVID-19

Calico and AbbVie initiate first-in-human study of ABBV-CLS-484

RMC-5552 enters phase I development for relapsed/refractory solid tumors

SMN gene therapy can result in too much of a good thing

Patient recruitment ongoing in phase III study of Tookad VTP in upper tract urothelial carcinoma

Stearoyl-CoA-desaturase inhibitor YTX-7739 shows efficacy in glioblastoma mouse models

NIH initiates study to assess allergic reactions to Moderna and Pfizer-BioNTech COVID-19 vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...